Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

20 Feb 2019

Abstract excerpt

BACKGROUND: The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy. Biomarkers to establish appropriate drugs usage are missing. Deficiency of the tumor suppressor CCDC6 determines PARP-inhibitor sensitivity. The CCDC6 levels are modulated by the deubiquitinase USP7. In this work we scored...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30786932
DOI: 10.1186/s13046-019-1087-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancerPMID 30786932Read ↗

USP5 facilitates bladder cancer progression by stabilizing the c-Jun proteinSemantic proximity Read ↗

Identification of cell division cycle 20 as a candidate biomarker and potential therapeutic target in bladder cancer using bioinformatics analysisSemantic proximity Read ↗

USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.Semantic proximity Read ↗

The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatmentSemantic proximity Read ↗

Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing C-mycSemantic proximity Read ↗

Doctors revise Declaration of HelsinkiSemantic proximity Read ↗

Response of the Urothelial Carcinoma Cell Lines to CisplatinSemantic proximity Read ↗

Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistanceSemantic proximity Read ↗

Cancer Genomic Profiling Identified Dihydropyrimidine Dehydrogenase Deficiency in Bladder Cancer Promotes Vulnerability to GemcitabineSemantic proximity Read ↗

FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLCSemantic proximity Read ↗

Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.